Keywords

chemiluminescence immunoassay, CLIA, diagnostic testing, ELISA, ELISPOT, enzyme-linked immunosorbent assay, enzyme-linked immunosorbent spot, IGRAs, immunocompromise, immunosuppressive medications, latent tuberculosis infection, PPD skin test, purified protein derivative test, screening and testing, TB, TST, tuberculin skin test, tuberculosis

Authors

1. Sierra, Carmen Josefa DNP, RN, CCTN
2. Downs, Charles A. PhD, ACNP-BC, FAAN

Abstract

Abstract: It is critical to detect latent tuberculosis infection through screening and testing individuals at high risk of progression to active tuberculosis, including patients who are immunocompromised. NPs should be familiar with available testing for accurate diagnosis in order to expedite treatment.